Beneficial effect of ubiquinol, the reduced form of coenzyme Q10, on cyclosporine nephrotoxicity

Akira Ishikawa, Yukio Homma

Department of Urology, Graduate School of Medicine, the University of Tokyo, Japan

ABSTRACT

Background: Cyclosporine (CyA) nephrotoxicity is partly due to some oxidative stress. Ubiquinol, the reduced form of coenzyme Q10 (rCoQ10), has recently gained attention for its anti-oxidative potential. The aim of this study is to evaluate the effect of rCoQ10 on a CyA nephrotoxic rat model.

Materials and Methods: Six-week-old male Wistar rats were divided into three groups (five animals each). Group 1 received a medium only. Group 2 received 30 mg/kg/day of CyA only. Group 3 received both the same dose of CyA and 600 mg/kg/day of rCoQ10. CyA and rCoQ10 were both given orally for four weeks. Systolic blood pressure (BP), daily urinary albumin secretion (u-Alb), serum creatinine (s-Cr) level, and super-oxide anion (SO) level in the renal tissue were measured and compared among those three groups. Immunohistochemistry using an antibody for the transforming growth factor-beta (TGF-beta) was also examined.

Results: BPs, u-Albs, s-Crs, and SO levels of groups 1, 2, and 3 were 114 ± 3, 132 ± 4, and 129 ± 5 mmHg, 2.6 ± 0.5, 42.1 ± 7.2, and 22.8 ± 3.4 micro-g/day, 1.1 ± 0.2, 1.7 ± 0.2, and 1.3 ± 0.2 mg/dl, and 224 ± 84, 1251 ± 138, and 512 ± 109 RLU/g kidney respectively. U-Albs, s-Crs, and SO levels were significantly ameliorated by rCoQ10. Micro-vacuolar changes and TGF-beta positive deposits in the proximal renal tubular cells of CyA group rats disappeared in those of CyA and rCoQ10 group rats.

Conclusion: rCoQ10, an antioxidants, may have potential for preventing CyA nephrotoxicity.

INTRODUCTION

Cyclosporine (CyA), a potent immunosuppressant, has a nephrotoxic side effect. Decrease of glomerular filtration rate caused by renal arteriolar spasms and renal interstitial fibrosis induced by transforming growth factor-beta (TGF-beta) upregulation, two major characteristics of CyA nephrotoxicity, are both evoked by some CyA-derived oxidative stress (1,2). Therefore, it is expected that antioxidants have benefits against the nephrotoxic side effects of CyA. Recently, ubiquinol, the reduced form of coenzyme Q10 (rCoQ10), a dietary supplement, has gained attention for its anti-oxidative potential (3). The following animal study was carried out to evaluate the effect of rCoQ10 on CyA nephrotoxicity.
animal care and the research protocols conformed to the principles outlined by the ethical committee for animal study in the University of Tokyo.

Six-week-old male Wistar rats were divided into three groups (five animals each). Group 1 received a medium (i.e. olive oil) only. Group 2 received 30 mg/kg/day (i.e. experimentally nephrotoxic dose (4)) of CyA only. Group 3 received both the same dose of CyA and 600 mg/kg/day of rCoQ10 (Kaneka, Osaka, Japan). CyA was dissolved in olive oil at a concentration of 20 mg/ml and given orally once a day using a gastric tube. RCoQ10 was mixed with standard chow at a rate of 0.6% and fed to each rat. Both were given for four weeks.

Systolic blood pressure (BP) of each rat was monitored every week using a tail-cuff method (BP-98A, Softron, Tokyo, Japan). Twenty-four-hour urine of each rat was collected using metabolic cages on the last day and urinary albumin excretion (u-Alb) was measured by an enzyme-linked immunosorbent assay (AKRAL-120, Shibayagi, Gunma, Japan). On the last day, blood sample was obtained from each rat and serum creatinine (s-Cr) level was measured by traditional Jaffe’s method using alkaline picrate (5). Whole blood CyA (WB-CyA) level was also examined by the fluorescence polarization immunoassay method. Superoxide anion levels in the whole kidney were checked by a lucigenin chemiluminescence method as previously reported (6).

Immunohistochemistry of the kidney using TGF-beta antibody (sc-146, Santa Cruz Biotechnology Inc., Santa Cruz, California, U.S.A.) was also performed.

Table 1 - Changes of systolic blood pressure (BP), daily urinary albumin excretion (u-Alb), serum creatinine (s-Cr) level, super-oxide anion (SO) level in the kidney.

<table>
<thead>
<tr>
<th></th>
<th>BP (mmHg)</th>
<th>u-Alb (micro-g/day)</th>
<th>s-Cr (mg/dl)</th>
<th>SO (RLU/g kidney)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control (n = 5)</td>
<td>113.6 ± 2.6</td>
<td>2.6 ± 0.5&quot;</td>
<td>1.1 ± 0.2</td>
<td>224 ± 84</td>
</tr>
<tr>
<td>CyA (n = 5)</td>
<td>132.4 ± 3.8'</td>
<td>42.1 ± 7.2&quot;</td>
<td>1.7 ± 0.2'</td>
<td>1251 ± 138&quot;</td>
</tr>
<tr>
<td>CyA + CoQ (n = 5)</td>
<td>129.2 ± 4.6'</td>
<td>22.8 ± 3.4&quot;</td>
<td>1.3 ± 0.2&quot;</td>
<td>512 ± 109&quot;</td>
</tr>
</tbody>
</table>

* P < 0.001 vs. Control; " p < 0.001 with each other; ' p < 0.01 vs. CyA; " p < 0.0001 vs. Control & CyA + CoQ; "' p < 0.002 vs. Control

Statistical analyses were done using ANOVA and subsequently Fisher’s PLSD test. The data are presented as mean ± SEM.

RESULTS

In 6-week-old male Wistar rats, 30 mg/kg/day of CyA for 4 weeks increased BP compared with control (113.6 ± 2.6 vs. 132.4 ± 3.8 mmHg, p < 0.001). U-Alb was elevated with CyA administration (2.6 ± 0.5 vs. 42.1 ± 7.2 micro-g/day, p < 0.001) and s-Cr was also increased by CyA (1.1 ± 0.2 vs. 1.7 ± 0.2 mg/dl, p < 0.001). RCoQ10 could not ameliorate hypertension (129.2 ± 4.6 mmHg, NS vs. CyA group); however, it could improve albuminuria (22.8 ± 3.4 micro-g/day, p < 0.001 vs. CyA group) and s-Cr elevation (1.3 ± 0.2 mg/dl, p < 0.01 vs. CyA group, Table-1). No significant difference was seen between WB-CyA levels of groups 2 and 3 (528 ± 94 vs. 498 ± 85 ng/ml).

Although CyA administration enhanced renal oxidative stress in 6-week-old male Wistar rats (224 ± 84 vs. 1251 ± 138 RLU/g kidney, p < 0.0001), rCoQ10 diminished SO generation from kidney (512 ± 109 RLU/g kidney, p < 0.0001 vs. CyA group, Table-1).

Micro-vacuolar changes and TGF-beta positive deposits observed in the proximal tubular cells of CyA group both disappeared by rCoQ10 administration (Figure-1).

DISCUSSION

In the present study, we demonstrated that rCoQ10, ubiquinol, ameliorated albuminuria...
Figure 1 - Immunohistochemistry Renal tissue stained with a TGF-beta antibody (sc-146, Santa Cruz Biotechnology Inc., Santa Cruz, California, U.S.A).

and s-Cr elevation associated with the reduction of oxidative stress upregulation in the kidneys of 6-week-old male and CyA-loaded Wister rats. RCoQ10 also diminished TGF-beta expression in the proximal renal tubular cells.

There are several animal and clinical studies suggesting that antioxidative agents have some preventive effect of CyA nephrotoxicity (7-12). In 2004, Dlugosz et al reported the benefit of CoQ10 on renal transplant recipients for the first time (13); however, they used ubiquinone, the oxidized form of CoQ10. Thus, the novelty of our present study is that we could demonstrate the apparent beneficial effects of ubiquinol, the reduced form of CoQ10, with its anti-oxidative potential on CyA nephrotoxic rat model. Actually, there are two forms of CoQ10, the oxidized (ubiquinone) and the reduced (ubiquinol). Both can be taken orally with few side effects (3). Ubiquinone is changed to ubiquinol when it reaches lymphatics through small intestine (14). As a result, more than a half of total CoQ10 in the body is the reduced form in many human tissues (15). Orally administered ubiquinol significantly increases the amount of the reduced form of CoQ10 (16).

Antihypertensive effect of CoQ10 (including ubiquinol) is still controversial (15,17,18). For example, Mori et al reported that ubiquinone, the oxidized form of CoQ10, showed no independent effect on blood pressure and could not reduce urinary protein in patients with chronic renal disease (17). In our present study with rCoQ10, no significant reduction of BP was observed. Our previous animal study revealed that CyA induced hypertension might be introduced by the activation of intrarenal renin-angiotensin axis (4). Therefore, reno-protection by rCoQ10 would be accomplished through another route. Antihypertensive treatment itself is essential for the complete control of CyA nephrotoxicity.

TGF-beta is known as one of chemical mediators for tissue fibrosis (19,20). Renal interstitial fibrosis is the irreversible histological damage observed in some long-term CyA-treated renal allografts (21). RCoQ10 might have potential to prevent chronic renal injury and improve the long-term outcome of renal transplantation by diminishing TGF-beta expression.

Since there was no significant difference between WB-CyA levels of groups 2 and 3, rCoQ10 might have had no interaction with CyA.

In conclusion, we demonstrated some beneficial effect of rCoQ10 against CyA nephrotoxicity probably due to its antioxidant action.

**ABBREVIATIONS**

CyA: cyclosporine  
rCoQ10: reduced form of coenzyme Q10  
BP: systolic blood pressure  
u-Alb: daily urinary albumin secretion  
s-Cr: serum creatinine  
WB-CyA: whole blood cyclosporine  
SO: super-oxide anion,  
TGF-beta: transforming growth factor-beta

**CONFLICT OF INTEREST**

None declared.
REFERENCES


EDITORIAL COMMENT

The evaluation of antioxidants substances is one of the most promising research lines on the 21th century. The well known harmful effects of free radicals and their involved mechanisms on oxidative stress are even more studied nowadays. The constant search for products or substances with the objectives to stop or break this depletory process has shown lots of progression, culminating on many potential active principles for future drugs to treat this kind of cell damage.

The article discusses the potential beneficial effects of ubiquinol over the oxidative stress caused by Cyclosporine, one potent immunosupressor commonly used by patients submitted to kidney transplantation. The study performed on Winstar rats has shown some beneficial of ubiquinol over the nephrotoxicity exerted by Cyclosporine. Understanding the correct mechanisms of oxidative stress on many different situations and how to combat it, may open a space for new researches for the development of drugs or medicines to help to improve the global survival of patient/graft dependent of immunosuppressors.

Dr. Fabio Tadeu Ferreira
Hospital Municipal Mario Gatti, Campinas
Av. Prefeito Faria Lima, 340, Parque Itália
Campinas, SP, 13036-220, Brazil
E-mail: fabio.urologia@gmail.com